Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 20/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | GPR183 | P32249 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL471183 | 1.00 | F2R (0.56) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| SCHEMBL14203696 | 1.00 | F2R (0.56) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| SCHEMBL13199852 | 1.00 | F2R (0.56) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| SCHEMBL13090681 | 0.92 | F2R (0.56) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| SCHEMBL13199859 | 0.92 | F2R (0.56) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| SCHEMBL752041 | 0.92 | F2R (0.56) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| SCHEMBL13480175 | 0.91 | F2R (0.55) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| SCHEMBL14203695 | 0.86 | F2R (0.62) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| SCHEMBL13603617 | 0.86 | F2R (0.58) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| SCHEMBL471689 | 0.86 | F2R (0.62) | F2RABCB11ADORA3CHRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302745-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | THIRUVENGADAM TIRUVETTIPURAM K (US) | 2012-11-29 | — | — | US | disclosed |
| US-8273790-B2 | Exo-selective synthesis of himbacine analogs | SCHERING CORPORATION (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120142914-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | TOPROL ACQUISITION LLC | 2012-06-07 | — | — | US | disclosed |
| US-8138180-B2 | Exo-selective synthesis of himbacine analogs | SCHERING CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100267947-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | SCHERING CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-7772276-B2 | Exo-selective synthesis of himbacine analogs | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267947-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | CHKB, BDKRB1, EDNRB | F2R 70/4885ABCB11 3512/4885ADORA3 146/4885 |
| US-20120302745-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | CHKB, BDKRB1, EDNRB | F2R 70/4885ABCB11 3512/4885ADORA3 146/4885 |
| US-20120142914-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | CHKB, BDKRB1, EDNRB | F2R 70/4885ABCB11 3512/4885ADORA3 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.